Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Neurology

Background:

• Heparin coating is used in cardiopulmonary bypass (CPB) circuits to improve clinical outcomes.
• Previous research has not fully explored the impact of heparin coating on cognitive function and memory disturbances post-surgery.

Purpose of the Study:

• To investigate the influence of different heparin coatings on brain function and memory in patients undergoing coronary bypass surgery.
• To assess the safety and clinical efficacy of heparin-coated cardiopulmonary bypass.

Main Methods:

• Randomized trial of 300 low-risk patients undergoing coronary bypass surgery.
• Comparison of three groups: Carmeda Bioactive Surface, Baxter Duraflo II, and a control group.
• Assessment of clinical outcomes, S100 release (biomarker for brain damage), and memory function via questionnaires.

Main Results:

• No significant differences in clinical outcomes or neurological injury (S100 release, memory impairment) were observed between heparin-coated and control groups.
• Heparin-coated groups showed reduced blood loss, lower transfusion requirements, and decreased postoperative creatinine elevation.
• The Duraflo group exhibited a lower incidence of atrial fibrillation.

Conclusions:

• Heparin coating in cardiopulmonary bypass appears safe, with no adverse effects on neurological outcomes or memory.
• While clinical outcomes were similar, heparin coating may offer benefits in reducing blood loss and transfusion needs.
• The type of heparin coating used did not appear to influence neurological injury or clinical outcomes.